HAL (France)
open access
Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis
Background Nirsevimab was introduced to prevent Respiratory Syncytial Virus (RSV) bronchiolitis in infants. Despite its proven effectiveness and similar guidelines across Europe, bronchiolitis reduction varied across Europe. This study explored whether nirsevimab coverage among targeted populations
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis#238177
- Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.#898683
- Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009#1057694
- Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis#456069
- How Pandemics Have Reshaped the Respiratory Virus Data Landscape in Europe: Scoping Review#1166173
Record · ID 1299304
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive